> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Regeneron Not Moving Eye Drug Combo Into Phase 3
- URL: https://www.fdaweb.com/regeneron-not-moving-eye-drug-combo-into-phase-3/
- Published: 2017-11-27T12:00:00.000Z
- Updated: 2026-09-14T23:03:30.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5140200

Regeneron Pharmaceuticals says two Phase 2 studies looking at adding investigational drug nesvacumab to the company’s already-approved Eylea (aflibercept) injection did not provide “sufficient differentiation” to move into Phase 3 development. The RUBY study examined patients with diabetic macular edema (DME) and the ONYX study evaluated patients with wet age-related macular degeneration (wet AMD). Results with Eylea, which is currently indicated for wet AMD, DME and macular edema following retinal vein occlusion, were consistent with findings from previous clinical studies, the company says.

The two randomized and active-controlled studies were designed to investigate whether a combination of aflibercept and nesvacumab offered additional benefits over aflibercept monotherapy. Results will be submitted for presentation at a future medical meeting, Regeneron says. The proposed combination was being jointly developed with Bayer AG under a [global collaboration agreement](http://investor.regeneron.com/releasedetail.cfm?releaseid=962065&ref=fdaweb.com).  

Nesvacumab is described as an angiopoietin2 (Ang2) antibody, and it was discovered by scientists at Regeneron as part of a family of vascular growth factors. The company had earlier reported preclinical data demonstrating that angiopoietins act together with Eylea to promote the formation and maturation of blood and lymphatic vessels in the eye. It was believed that together the drugs had the potential to influence new blood vessels development and the permeability of blood vessel walls in certain diseases of the eye, Regeneron said when planning the stuidies.